Francis Medical Founder and Chief Technology Officer, Michael Hoey, joins The Focal Therapy Clinic OnFocus podcast to discuss a new approach to focal therapy, water vapor therapy, and its adoption into medical practice.
September 15, 2021: Francis Medical today announced the completion of the company’s $55.0 million Series B equity financing. The company plans to use the Series B proceeds to fund the development of its proprietary prostate cancer treatment through FDA 510(k) approval, which includes a pivotal clinical study (VAPOR 2) for the management of prostate cancer, scheduled to begin enrollment in August 2022.
Press Release: Francis Medical Announces Positive Data from VAPOR 1 IDE Study for Water Vapor Ablation of Prostate Cancer
June 8, 2021: Francis Medical announces positive data from its Vapor 1 IDE Study for water vapor ablation of prostate cancer. These promising results support the intent of this therapy to manage clinically significant disease while decreasing morbidities associated with currently used prostate cancer treatments.
In an interview for Medical Alley's "For the Record," the founder and CTO of Francis Medical, Michael Hoey, shares why he sought a more compassionate approach for treating prostate cancer and how he discovered water vapor technology. He also gives a window into how things are progressing at Francis Medical...
September 30, 2020: CCX Media visited Francis Medical to interview President and CEO Mike Kujak, and get an inside look at how Francis Medical is thriving and moving forward during the COVID-19 pandemic. This two-minute video includes recent news about a $4M investment by Coloplast.
September 29, 2020: Francis Medical Adds Urology Company Coloplast to Its Roster of Investors. The $4 million equity investment will support the company in optimizing its product design and executing a pivotal U.S. study.
This video demonstrates how water vapor therapy will provide a revolutionary new prostate cancer treatment that is tough on prostate cancer yet gentle on patients.
June 17, 2020: CCX Media visited Francis Medical for exclusive interviews with CEO and President, Mike Kujak, and Founder and CTO, Michael Hoey. Their two-minute video includes an explanation of our revolutionary water vapor therapy, as well as plans for the future, including our VAPOR 1 clinical study.
Press Release: Francis Medical Announces First Patient Enrolled in VAPOR 1 IDE Study for Water Vapor Ablation of Prostate Cancer
June 9, 2020: Francis Medical, Inc. announces the enrollment of their first patient in the company’s VAPOR 1 clinical study, an early feasibility study evaluating the safety and efficacy of the company’s minimally invasive water vapor ablation therapy for the treatment of prostate cancer.
On the heels of successful patient treatments in Panama City, Panama, Francis Medical is overcoming challenges brought on by the COVID-19 pandemic to bring their ground-breaking water vapor technology to men dealing with prostate cancer.
October 16, 2019: Dr. Jonathan Jarow joins Francis Medical, Inc. as the company’s chief medical officer (CMO) to lead Francis Medical’s clinical and regulatory efforts, including the VAPOR trials evaluating water vapor ablation as a minimally invasive treatment for prostate cancer.
December 17, 2018: Francis Medical, Inc. has been featured in BioWorld MedTech, a leading news source of advances in medical technology.
December 13, 2018: Francis Medical announces the completion of a $18.0 million round of Series A funding. Arboretum Ventures led the Series A with co-investments from H2Oey Ventures (an affiliate of Solas BioVentures Fund), Tonkawa, and Boston Scientific. Francis Medical plans to use this capital to further develop the company's cancer ablation therapy.